Evaluation of CSF [cerebrospinal fluid] levels of Tarceva (OSI-774) [erlotinib] in patients with stage III non-small cell lung cancer and no CNS involvement undergoing treatment with Tarceva.

Trial Profile

Evaluation of CSF [cerebrospinal fluid] levels of Tarceva (OSI-774) [erlotinib] in patients with stage III non-small cell lung cancer and no CNS involvement undergoing treatment with Tarceva.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2011

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 10 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top